Metrics to compare | SLGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −231.3x | 7.1x | −0.4x | |
PEG Ratio | −2.51 | 0.04 | 0.00 | |
Price/Book | 4.7x | 1.9x | 2.6x | |
Price / LTM Sales | 13.1x | 2.4x | 3.0x | |
Upside (Analyst Target) | 148.6% | 16.8% | 49.1% | |
Fair Value Upside | Unlock | 11.8% | 6.3% | Unlock |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.